Effects of Abatacept in Patients With Early Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2020-03-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Abatacept; Methotrexate

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Rheumatoid arthritis (RA) diagnosis less than 6 months

• CRP > 3 mg/L or Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/h

• At least 3 swollen and 3 tender joints

• Anti-citrullinated protein antibodies (ACPA) positive

Exclusion Criteria:

• At risk for tuberculosis

• Have acute infection

• Have chronic or recurrent bacterial or serious latent viral infection

• History of malignancies in the last 5 years except squamous skin, basal skin or cervical carcinoma

• Previous treatment with any conventional or biologic Disease-modifying anti rheumatic drugs (DMARD)